Last reviewed · How we verify
5% sildenafil cream
At a glance
| Generic name | 5% sildenafil cream |
|---|---|
| Also known as | Topical treatment for Raynaud |
| Sponsor | Pontificia Universidad Catolica de Chile |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Sildenafil Vaginal Gel Co-treatment With Clomiphene Citrate in Infertile Women With Thin Endometrium (NA)
- Phase 2a Topical Sildenafil Proof-of-Concept Study in Men With Mild to Moderate ED (PHASE2)
- Study to Evaluate the Efficacy and Safety of SST-6007, a Topical Sildenafil Cream, Compared to Placebo in Women With Female Sexual Arousal Disorder (PHASE2)
- Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud (EARLY_PHASE1)
- A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women (PHASE1)
- Single-Dose Relative Bioavailability Study of SST-6006, a Topical Sildenafil Cream Versus Oral Sildenafil in Healthy Male Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 5% sildenafil cream CI brief — competitive landscape report
- 5% sildenafil cream updates RSS · CI watch RSS
- Pontificia Universidad Catolica de Chile portfolio CI